|
|
|
|
||
Re: What is still missing is an equity offeringI am not talking about investors, you and I, and others on this board. I am talking about the buyer. The buyer, if large as is speculated, has a competitive intelligence group that looks at all aspects of this buy. They do it for a living. I think they know more than we do. I would go further. They do know more than we do. They talk to others in the industry daily. They likely know whom they are bidding against. They have signed a confidentiality agreement that allows them more ACAD/pima information than we have. Breakthroughs happen and if it is your drug that gets hurt and you rely on its revenue stream, it has to be a consideration. They are paying billions, not thousands as we do. The buyer also has experienced sales/marketing people that know the pace of uptake in beacoup drugs. Pima is a new drug, so there will be disagreement, but they know a lot more than ACAD's marketing/sales people and we retail investors. All of this is why you usually do not get bids that exceed your individual investor expectations. Yes, they sometimes make horrendous mistakes about how much to pay for a company/drug ( but not usually). They pay the top people at the buyee company big bucks as they move on, another consideration. And the lawyers who create the term sheets always consider the worst of scenarios, and they slow the process down markedly. Your arguments are logical, but these negotiations are not, from my experience. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
9306 | Re: What is still missing is an equity offering | BelieverTim | 10 | 3/25/2017 7:35:12 AM |